First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening.

@article{Alldred2017FirstAS,
  title={First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening.},
  author={S Kate Alldred and Yemisi Takwoingi and Boliang Guo and Mary E. Pennant and Jonathan J. Deeks and James P. Neilson and Zarko Alfirevic},
  journal={The Cochrane database of systematic reviews},
  year={2017},
  volume={3},
  pages={
          CD012599
        }
}
BACKGROUND Down's syndrome occurs when a person has three copies of chromosome 21 (or the specific area of chromosome 21 implicated in causing Down's syndrome) rather than two. It is the commonest congenital cause of mental disability. Non-invasive screening based on biochemical analysis of maternal serum or urine, or fetal ultrasound measurements, allows estimates of the risk of a pregnancy being affected and provides information to guide decisions about definitive testing.  Before agreeing to… 

Figures and Tables from this paper

Prenatal serum screening for Down syndrome and neural tube defects in the United States: Changes in utilization patterns from 2012 to 2020
TLDR
Maternal serum screening for common aneuploidies has changed significantly in eight years with fewer laboratories, a shift toward larger laboratories and a 2.5-fold reduction in pregnancies tested, likely due to the introduction of cell-free DNA screening.
Non-invasive prenatal screening: A 20-year experience in Italy
The Contingent Prenatal Screening Test for Down’s Syndrome and Neural Tube Defects in West of Iran
TLDR
The contingent prenatal screening tests were found to be useful for estimation of Down’s syndrome as well as NTDs in both young and older mothers in west of Iran and should be performed for pregnant women before an invasive test for Down's syndrome.
Fetal Aneuploidy: Screening and Diagnostic Testing.
TLDR
Fetal cell-free DNA testing (noninvasive prenatal testing) performed at or after 10 weeks' gestation detects more than 99% of trisomy 21 cases, with a lower false-positive rate than traditional first- or second-trimester screening methods.
Challenges and controversies in prenatal genetic screening in the South African context
TLDR
An important safeguard to overcome the “relative risk” conundrum would be to inform all patients during pre-test counselling of an intermediate risk category generally between 1:300-1:1000 where cfDNA testing may be considered, at the parents’ own discretion.
Novel perspectives in fetal biomarker implementation for the noninvasive prenatal testing
TLDR
This review summarizes the principles, methods, advantages, and limitations of noninvasive prenatal testing for the detection of aneuploidy, CNVs and single-gene disorders and discusses and analyzes clinical parameters and clinical application guidelines.
Down syndrome
TLDR
Comparisons of survival rates for Down syndrome over time are complicated by changing birth prevalence and other factors such as improved neonatal ascertainment and uneven improvement in survival across different age groups, which influences the data on survival curves.
Application of intelligent algorithms in Down syndrome screening during second trimester pregnancy
TLDR
Intelligent algorithms based on the synthetic minority over-sampling technique (SMOTE)-Tomek and adaptive synthetic sampling over- sampling techniques to preprocess the dataset of prenatal screening information achieved good results on the DS screening dataset.
Integrating multiple of the median values of serological markers with the risk cut-off value in Down syndrome screening.
TLDR
Integrating MoM values of serological indicators can appropriately increase detection rate when interpreting the results of Down syndrome screening.
A Paradigm Shift: Considerations in Prenatal Cell-Free DNA Screening.
TLDR
Early studies suggest that routine application of cell-free DNA screening is both feasible and effective, although significant economic and quality control considerations remain.
...
1
2
3
4
...

References

SHOWING 1-10 OF 638 REFERENCES
First trimester serum tests for Down's syndrome screening.
TLDR
The aim of this review was to estimate and compare the accuracy of first trimester serum markers for the detection of Down's syndrome in the antenatal period, both as individual markers and as combinations of markers.
Urine tests for Down's syndrome screening.
TLDR
To estimate and compare the accuracy of first and second trimester urine markers for the detection of Down's syndrome, a sensitive and comprehensive literature search was carried out and 19 studies involving 18,013 pregnancies were included.
Second trimester serum tests for Down's Syndrome screening.
TLDR
Tests involving two or more markers in combination with maternal age are significantly more sensitive than those involving one marker, and the impact of maternal age on test performance in subgroup analyses is investigated.
Integrated screening for Down's syndrome based on tests performed during the first and second trimesters.
TLDR
A new screening method in which measurements obtained during both trimesters are integrated to provide a single estimate of a woman's risk of having a pregnancy affected by Down's syndrome is proposed.
Maternal Serum CA125 is Not a Second Trimester Marker for Down's Syndrome
  • K. Spencer
  • Medicine
    Annals of clinical biochemistry
  • 1991
TLDR
It is considered the possibility that CA125, if truly an indicator of abnormal karyotype, may still be elevated in viable second trimester pregnancies and may prove to be a useful screening test for Down’s syndrome or as an adjunct to other serological marker.
Prenatal screening for Down's syndrome with use of maternal serum markers.
TLDR
This data indicates that serum levels of unconjugated estriol and chorionic gonadotropin, which are abnormally low and abnormally high, respectively, in women carrying fetuses affected by Down's syndrome can be detected by measuring maternal serum alpha-fetoprotein during the second trimester in the general population of pregnant women.
First-trimester screening for chromosomal abnormalities.
TLDR
There is extensive evidence that effective screening for major chromosomal abnormalities can be provided in the first trimester of pregnancy, and a further improvement in the effectiveness is likely to be achieved by a risk-orientated two-stage approach.
Prospective study of prenatal screening for Down's syndrome with free beta human chorionic gonadotrophin.
TLDR
The benefit of a high detection rate with this approach and the additional anomalies identified should encourage others to introduce screening programmes for Down's syndrome that use free beta human chorionic gonadotrophin and alpha fetoprotein.
Cross-trimester repeated measures testing for Down's syndrome screening: an assessment.
TLDR
The established modelling methodology for assessing screening performance may be optimistically biased and should be interpreted with caution, and the Bayesian analysis, which shows evidence of benefit, is based on strong distributional assumptions and should not be regarded as confirmatory.
...
1
2
3
4
5
...